Navigation Links
012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007
Date:2/26/2008

19,804 21,920 5,149

Deferred taxes 7,247 3,445 1,884

Total current assets 456,264 260,424 118,633

Investments

Long-term trade receivables 3,460 2,951 900

Deferred taxes 14,648 15,650 3,809

Assets held for employee

severance benefits 18,453 15,924 4,798

Total Investments 36,561 34,525 9,507

Property and equipment, net 160,211 155,367 41,656

Other assets, net 295,592 276,219 76,857

Other intangible assets, net 202,376 234,871 52,620

Goodwill 411,171 410,156 106,909

Total assets 1,562,175 1,371,562 406,182

012 Smile.Communications Ltd.

Consolidated Balance Sheets (cont'd)

Convenience

translation

into

U.S. dollars

$1 = NIS

3.846

December 31 December 31

2007 2006 2007

(Unaudited) (Audited) (Unaudited)

NIS thousands $ thousands

Current liabilities

Short-term bank credit 4,750 331,639 1,235<
'/>"/>

SOURCE 012 Smile.communications Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. 012 Smile.Communications to Deploy Extensive WiFi Internet Access System for Sheba Medical Center
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. Haemacure Reports Third Quarter 2007 Results
4. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
5. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
6. MDS Reports Third Quarter 2007 Results
7. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
8. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
9. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
11. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ons announces a highly effective and unconventiona...to make an economic recovery. , ...he type of challenge that could send ailing holida...vid Benton, business growth expert and author of t...The Rfactor Intensive . “Fear is one of th...
(Date:11/25/2009)...-SentinelleMedicalInc.,aleadingmanufacturerofMagne...ScientificInc.,aleadingproviderofsoftwareenablingt...east4DAdvancedVisualizationsoftware. ,, Thisinn...ientbasedmedicalimagingofferinginthemarket.Calgary...rintaccess-requiringnosoftwaredownload,andrunsonan...
(Date:11/25/2009)...BayAreaAirQualityManagementDistrictisissuingthesea... forThursday,November26,2009whichbansburningwood,...sandoutdoors. ,, "Cold,stillweatherwillcontribu...,executiveofficeroftheAirDistrict."We,reaskingBayA...ellowcommunitymembersthisThanksgiving,andnottoburn...
(Date:11/25/2009)... simple question has been the focus of intense res...ulates High Blood Pressure in Mice & Men, Does st...n has been the focus of intense research for many ...tablished a link between a novel gene, phosducin, ...as well as humans. The studies were directed by sc...
(Date:11/25/2009)...toms, study finds , , WEDNESDAY, Nov. 2...e among the potential problems faced by long-term ...th cisplatin-based chemotherapy, a new study has f...treated for unilateral testicular cancer between 1...onducted from 1998 to 2002. , The researchers f...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
...(Nasdaq: PARS ) announced today that it has comp...extofisopam trial for Irritable Bowel Syndrome IBS...ld achieve the objectives of the trial. As the Ph...(1) determine the best dose to move into Phase 3, ...
...row? , , WASHINGTON, March 4 The Association of ... following statement by Kathryn Serkes, Director o...nt,s Healthcare Summit on March 5, 2009: , , "We... lost in the mail. , , "It,s interesting that r...
...as in general, study suggests , , WEDNESDA...at increase cocaine addicts, risk of paranoia have...tudy of almost 4,000 people of African and Europea...aine dependence and cocaine-induced paranoia. , Th...
...e, the first South Florida publication dedicated t..., nutrition, health and sports for men and women, ... the 2009 FAME Awards (FOLIO: Awards for Magazine ...n magazine-powered events, SOBeFiT beat out fina...
...t in a 6-3 decision upheld a Vermont jury,s decisi... Court case Wyeth v. Levine could hold the drug ma...ed -- which included the loss of her arm -- after ...rsight of drug labeling doesn,t prevent the filing...
... Inc. (OTC Bulletin Board: BKYI), a leader in wire...tification solutions, today announced that on or b...tates District Court for the Southern District of ...their complaint, those investors have alleged that...
Other Medicine News:Health News:Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved 2Health News:Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved 3Health News:AAPS Doctors: White House Healthcare 'Prom' Invitations 'Lost in the Mail' 2Health News:Gene Variant Tied to Cocaine-Induced Paranoia 2Health News:SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards 2Health News:SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards 3Health News:SOBeFiT Magazine Wins Best Magazine Launch Party at 2009 FAME Awards 4Health News:BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2Health News:BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3
(Date:11/25/2009)...UNSWICK,N.J.,Nov.25/PRNewswire/--SwissrayInternati...raphy( ddR )systems,announcedtodaythatitsoperation...ermviewtowardsgrowingSwissray,smedicalimagingbrand...perty,aswellascontractsandinventory.After25yearsof...leveloftechnologicaladvancementswithstableandstead...
(Date:11/25/2009)...GO,Nov.25/PRNewswire-FirstCall/--NuVasive,Inc.(Nas...ngproductsforminimallydisruptivesurgicaltreatments...ecallonMonday,November30,2009,at5:30p.m.ET/2:30p.m...ivetoreimbursementfortheCompany,sproductsandwillin...nandanswersession.Thedial-innumbersare1-877-407-40...
(Date:11/25/2009)...K,Nov.25/PRNewswire/--Reportlinker.comannouncestha...: ,, PainManagement-GlobalTrends ,, htt...--Global-Trends.html ,, Widespreadavailability...dtheadventofnewdrugshaveacceleratedthepaceofgrowth...bursementstructurecontinuetoshapedemandforservices...
Breaking Medicine Technology:Swissray International Announces New Ownership 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Why Save Bad Teeth 3F Dental Heroics Unnecessary and Failure Prone 55554 1Why Save Bad Teeth 3F Dental Heroics Unnecessary and Failure Prone 55554 2The Feinstein Institute for Medical Research Discovers the Role of Progesterone and Pre Term Labor 55550 1The Feinstein Institute for Medical Research Discovers the Role of Progesterone and Pre Term Labor 55550 2Nuvilex Introduces Last Shot Hangover Remedy 28TM 29 Video 55546 1Nuvilex Introduces Last Shot Hangover Remedy 28TM 29 Video 55546 2
...ill evaluate R7128 1000mg BID in HCV genotype 1, ...HCV genotypes 2 or 3 treatment-...Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced do...udy of R7128 in combination with Pegasys(R) (pegin...oth treatment-naive and,treatment-experienced pati...
...ast to Review Data Tuesday, May 13 at 1:00 p.m. ED...RCELONA, Spain and MENLO PARK, Calif., May 13 /PRN... today announced positive six-month follow-up,data...d the safety and,efficacy of the Custom NX(R) drug...atients with coronary artery disease., The CUSTOM...
Other Medicine Technology:Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 2Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 3Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 4XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4
IDS Rapid One
Versatrek 240
Bax
Finstruments 404 Plate Washer
Medicine Products: